Clinical and Economic Benefits of Faster Phenotypic Antimicrobial Susceptibility Testing

Levi Kirwin, Director, Commercial Marketing, Accelerate Diagnostics

Levi Kirwin is the director of commercial marketing at Accelerate Diagnostics, with fifteen years' experience as a chemist, microbiologist, and life sciences/medical device marketing professionl. He has a BS Microbiology from Texas Tech University and MBA from the University of Tampa, and is committed to partnering with laboratory and clinical professionals alike to provide new diagnostic tools that save lives for patients with bloodstream infections

Sponsored by Accelerate Diagnostics

Clinical and Economic Benefits of Faster Phenotypic Antimicrobial Susceptibility Testing

Clinical microbiology has experienced an unprecedented wave of innovation due to the introduction of advanced testing such as PCR, MALDI-TOF, and PNA-FISH. The wave of new technologies has dramatically improved the time to pathogen identification result from culture, but has not impacted antimicrobial susceptibility testing: the definitive diagnostic result for changing antibiotic therapy in patients with bloodstream infections. This presentation explores the clinical need for faster phenotypic susceptibility testing using the Accelerate PhenoTest™ BC kit. Topics covered include the benefits to the patient and the economic benefits to the healthcare institution.

Earn PACE/CME Credits:

LabRoots on Social:
SnapChat: labroots_inc